🔗 Share this article

While the US proceeds with unprecedented adjustments to its vaccine recommendations, a particular individual appears unexpectedly: Høeg, a US-based sports medicine doctor and public health researcher who rose to prominence by casting doubt on Covid shots throughout the pandemic and has concentrated on alleged deaths following COVID-19 immunization in her short position at the US Food and Drug Administration (FDA).

Planned Overhauls to Pediatric Vaccine Schedule

Public health authorities were set to announce sweeping changes to the pediatric vaccination calendar earlier this month, aligning the US with the Danish national calendar, according to reports – a substantial departure that would put the US out of step with many the international standard with little proof for improved outcomes. The planned update has been delayed until the new year.

Rather than Vinay Prasad, Høeg is scheduled to present at the meeting. She was just designated interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to head the division this calendar year.

Consolidating Power at the Agency

This interim role might represent a strengthened alliance between the pharmaceutical and vaccine branches as Høeg and Prasad strengthen their influence at the agency – and it signals a greater focus upon rolling back already-approved vaccines at the FDA.

The new acting director has repeatedly called for discontinuing some pediatric immunization guidelines in the US so as to align more similar to Denmark, a country with universal health coverage and a citizenry about the population of the state of Wisconsin.

To date statements, she has kept her attention on immunizations – traditionally the responsibility of Prasad, director of the FDA’s CBER – instead of pharmaceutical oversight.

Questions Over Qualifications

The appointee has no obvious experience in pharmaceutical research, oversight or administrative roles, which has been typical for past heads of the CBER. She has been employed at the FDA as a senior adviser to the commissioner and the vaccine center since March.

“She doesn’t seem to have the necessary background” for leading the drug-regulation department, remarked Jonathan Howard. “She’s never run a scientific study. She lacks experience in leading a major agency. She lacks background in drug approvals.”

Past directors of CBER would “be deeply familiar with laws and regulations and the science of pharmaceutical innovation”, noted Janet Woodcock. “Objectively, she has not acquired the sort of resume that prior appointees who led the center have had.”

CDER has an immense workload at the agency, Woodcock stated.

“The public just focuses on the innovative therapies, but the off-patent medication office authorizes a multitude of off-brand pharmaceuticals. There’s a biosimilars program, OTC medication office and more, and all of those need to be supervised,” she noted. “The thing you don’t keep your eye on, that is precisely what that I always told people is going to cause problems.”

Additionally, a major management aspect to the role, which manages in excess of 5,000 staff members. “It is a enormous management job, if you do it right,” the former official concluded.

Response and Disputed Policies

When asked about inquiries about Høeg’s qualifications and whether this assignment indicates more teamwork among FDA leaders on immunizations, a press secretary stated that the “concerns rely on incorrect premises”.

“This background matches the responsibilities of her job,” the spokesperson stated, pointing to the months Dr. Høeg spent guiding the agency head on “medication safety and regulatory science, including predictive safety algorithms and shot safety tracking”.

In her interim role, Høeg assumes responsibility for the commissioner’s new fast-track approval initiative, a contentious rapid therapy clearance system that reportedly worried her predecessors. “How are these medications being selected for this voucher program? Who is making the calls?” Howard questioned. “There’s a lot of lack of transparency occurring at the agency right now.”

Broadly speaking, he remarked, “the FDA looks to be trending towards more relaxed oversight of pharmaceuticals, with the exception of vaccines.”

Documented Track Record on Immunizations

Concerning vaccines, Dr. Høeg has a more established, if concerning, track record, critics said. She released a analysis using unconfirmed public submissions to determine the frequency of heart inflammation after COVID-19 vaccination. She consulted for the state of Florida top health official Dr. Joseph Ladapo, who was said to have modified findings to indicate Covid vaccinations are riskier than they are.

Part of her “wish list” for the incoming government included revising regulations for novel immunizations and discontinuing “non-essential” immunizations, she remarked following the vote on a podcast. At the FDA, Dr. Høeg has reportedly floated the idea of preventing teenage boys from obtaining Covid vaccinations.

“She is an all-around dogmatist who starts off with her preconceived notions and tailors the evidence to accommodate the data in a highly disingenuous, dishonest way,” Dr. Howard stated.

Taking Control and a “Campaign of Retribution”

Dr. Høeg became part of other contrarians, {like|